Plasma Biomarkers May Help Target CAR-T Therapy for Multiple Myeloma
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.
CAR-T Therapy
Engineered CAR Cells Show Proof of Concept for Multiple Myeloma Therapy
Researchers sought to determine whether engineered affinity-optimized CD38 CAR-T cell therapy would have potential treating patients with multiple myeloma.
CAR T Cell Therapy May Not Improve Survival vs Chemotherapy in B-ALL After Allo-HSCT
Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.
Factors Leading to CAR T Cell Therapy Resistance in Patients With Large B-Cell Lymphoma
Researchers sought to identify factors that may contribute to failure with CAR T cell therapy in patients with LBCL.
ICER Releases Recommendations for Anti-BCMA Therapies for Multiple Myeloma
ICER analyzed the effectiveness of new treatments and their costs and impact on quality of life to develop recommendations for stakeholders seeing patients with MM.
Chimeric Antigen Receptor T-Cell Therapy Shows Positive Results in Pediatric Patients With B-Cell ALL
Researchers sought to determine the long-term safety and efficacy of KTE-X19 in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Cytokine Release Syndrome Manageable in Relapsed/Refractory Multiple Myeloma Treated With CAR-T Therapy
Researchers sought to analyze the occurrence and severity of cytokine release syndrome in patients with relapsed/refractory multiple myeloma who recieve CAR-T therapy.
CAR-T Therapy Effective in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether CAR-T therapy would be an effective treatment for patients with relapsed/refractory multiple myeloma.
CAR-T Cell Therapy Promising in Multiple Myeloma
Researchers sought to determine whether idecabtagene vicleucel, a CAR-T cell therapy, would be a viable treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
CAR T Cell Therapy Shows Benefits in Patients With R/R Indolent Non-Hodgkin Lymphoma
The ZUMA-5 trial studied whether CAR T cell therapy with axi-cel had any clinical benefits in patients with indolent NHL.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...